- Report
- June 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- January 2026
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- January 2026
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- December 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- November 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- September 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- September 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- September 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- July 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- June 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- May 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- June 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Training
- November 2026
- 5 Days
Global
€1916EUR$2,224USD£1,599GBP
€2275EUR$2,642USD£1,899GBP
- Training
- June 2026
- 3 Days
Global
€2635EUR$3,059USD£2,199GBP
- Report
- May 2026
- 369 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- December 2025
- 137 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Training
- November 2025
- 2 Days
Global
From €1362EUR$1,528USD£1,177GBP
€1603EUR$1,798USD£1,384GBP
- Report
- October 2025
- 109 Pages
Global
From €3076EUR$3,450USD£2,657GBP
- Report
- August 2025
- 205 Pages
Global
From €4413EUR$4,950USD£3,812GBP
- Report
- August 2025
- 165 Pages
United States
From €3522EUR$3,950USD£3,042GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more